Last Updated : Aug 02, 2017 02:01 PM IST | Source:

Hold Glenmark Pharmaceuticals; target of Rs 730: ICICI Direct

ICICI Direct has recommended Hold rating on Glenmark Pharmaceuticals with a target price of Rs 730 in its research report dated July 31, 2017.

  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Glenmark Pharmaceuticals

Revenues grew 20% YoY to Rs 2363 crore (I-direct estimate: Rs 2146 crore) mainly due to 50% YoY growth in the US to Rs 1045 crore (I-direct estimate: Rs 920 crore) led by gZetia Exclusivity. India business surprisingly grew 15% YoY to Rs 616 crore (I-direct estimate: Rs 437  crore) despite GST transition EBITDA margins increased 519 bps YoY to 24.4% (I-direct estimate: 18.6%) attributable to lower raw material, employee and other  expenses. EBITDA increased 52% YoY  to Rs 578 crore (I-direct  estimate: Rs 399 crore).

Catch LIVE updates of RBI Monetary Policy


We reduce our FY18E, FY 19E EPS estimates by 18%, 20%, respectively. Accordingly, we arrive at our new target price of Rs 730 based on 18x F Y19E EPS of Rs 40.6.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

First Published on Aug 2, 2017 01:29 pm